Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology: brnw.ch/21wNKGK Alexander Sherry Ethan Ludmir MD Pavlos Msaouel Erik van Zwet

Proud to present the results of the EXTEND breast basket led by #JayReddy from MD Anderson Cancer Center in the IJROBP - The Red Journal . This is a randomized trial of oligometastatic breast cancer patients randomized to +/- MDT. Unfortunately not all trials were positive. shorturl.at/vhaTy

Does SBRT for oligorecurrent #prostatecancer improve overall survival as compared to SOC? WOLVERINE reporting on STOMP, ORIOLE, EXTEND and ARTO. Presented by Chad Tang, MD at #GU25.

👥Case-Based Session: Evolving Landscape of the Management of Oligometastatic Disease #GU25 🐺Dr Chad Tang, MD presenting Abs15 "World-wide oligometastatic prostate cancer (omPC)meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis

Just 2 incoming Mayo Clinic Radiation Oncology faculty enjoying the views & company at the JAMA Oncology reception. #ASCO25

1/5 How reproducible are phase III oncology trials? 📊 With Alexander Sherry Erik van Zwet Ethan Ludmir MD et al. We analyzed 632 RCTs (~496,000 pts). The data offer both reassurance and caution for clinicians and researchers. pubmed.ncbi.nlm.nih.gov/40628175/ 👇#MsaouelLab